September 24, 2008
Steroid-Induced Osteonecrosis: THE NUMBER OF LESIONS IS RELATED TO THE DOSAGE
By Zhang, N-F Li, Z R; Wei, H-Y; Liu, Z-H; Hernigou, P
Severe acute respiratory syndrome (SARS) is a newly described infectious disease caused by the SARS coronavirus which attacks the immune system and pulmonary epithelium. It is treated with regular high doses of corticosteroids. Our aim was to determine the relationship between the dosage of steroids and the number and distribution of osteonecrotic lesions in patients treated with steroids during the SARS epidemic in Beijing, China in 2003. We identified 114 patients for inclusion in the study. Of these, 43 with osteonecrosis received a significantly higher cumulative and peak methylprednisolone-equivalent dose than 71 patients with no osteonecrosis identified by MRI. We confirmed that the number of osteonecrotic lesions was directly related to the dosage of steroids and that a very high dose, a peak dose of more than 200 mg or a cumulative methylprednisolone-equivalent dose of more than 4000 mg, is a significant risk factor for multifocal osteonecrosis with both epiphyseal and diaphyseal lesions. Patients with diaphyseal osteonecrosis received a significantly higher cumulative methylprednisolone-equivalent dose than those with epiphyseal osteonecrosis. Multifocal osteonecrosis should be suspected if a patient is diagnosed with osteonecrosis in the shaft of a long bone.
Severe acute respiratory syndrome (SARS) is a newly described infectious disease caused by the severe acute respiratory syndrome- corona-virus (SARS-CoV) which principally damages the cells of the immune system and pulmonary epithelium.5,6 Treatment with steroids is required.7,8 Our aim was to analyse the relationship between the dosage of steroids and the number and distribution of osteonecrotic lesions seen in patients treated during the SARS epidemic in Beijing, China in 2003.
Patients and Methods
SARS first emerged in southern China during the final quarter of 2002. In the early Spring of 2003 the epidemic reached Beijing and many patients received high doses of steroids.8 Between September 2003 and January 2004 the Beijing Municipal Government organised the follow-up of medical staff and related personnel who had contracted the disease during the treatment and transportation of infected patients. A total of 426 staff, mostly doctors and nurses, were identified as having been infected and treated between March and May 2003. The diagnosis was confirmed using established World Health Organisation diagnostic criteria.9 The patients in our study were generally healthy before becoming infected so we had the opportunity to study the relationship between the dosage of steroid and osteonecrosis in a population without an apparent clinical predisposition. Patients were divided into five groups for their follow-up based on where they worked. Only the 121 patients from the same geographical zone were followed up in a designated SARS hospital which could offer MRI evaluation of any area of osteonecrosis. The study was approved by the hospital Ethics Committee and all patients provided written informed consent.
Table I. Details of the 114 post severe acute respiratory syndrome patients in the two groups
Follow-up was by questionnaire which noted clinical details (Table I) and physical examination. Demographic data were collected by nurses and clinical data by orthopaedic surgeons (N-FZ, ZRL, H- YW, Z-HL) who belonged to a specialist group for the diagnosis and treatment of post-SARS osteonecrosis and had been appointed by the Beijing Municipal Government.
Both the dosage and duration of steroid use were retrieved from the hospital records. The dosage was recorded as cumulative, peak and mean daily methylprednisolone or its equivalent. A conversion factor of 1:1.25 was used to calculate the methylprednisolone- equivalent dosage of methylprednisolone and prednisone.
MRI using a 1.5-T magnet (GE Sigma Profile/Gold USA; General Electric Medical Systems, Milwaukee, Wisconsin) was performed on both shoulders, wrists, hips, knees, ankles and on the humeral, femoral and tibial shafts. For all, coronal T^sub 1^-weighted spin- echo sequence was used (590/20 repetition time msec/echo time msec, a section thickness 5 mm, intersection gap 1 mm, field of view of 350 mm, matrix 256 x 256 pixels). If the diagnosis could not be established clearly on coronal T^sub 1^-weighted images, sagittal and axial T^sub 1^- and T^sub 2^-weighted images were obtained.
Osteonecrosis was defined by its location, either subchondral or intramedullary, in which it was demarcated by a distinct marginal rim with low signal intensity that encompassed medullary fat on the T^sub 1^-weighted images. Multifocal osteonecrosis was defined as disease involving three or more separate sites.2,3 The diagnosis was established jointly by radiologists and orthopaedic surgeons. The Association Research Circulation Osseous (ARCO) system was used for staging.10
Statistical analysis. SPSS version 11.0 for Windows (SPSS Inc., Chicago, Illinois) was used for all statistical analyses. All the data were coded, checked and entered into SPSS data sets. Means and SDs were calculated to characterise continuous variables. An independent samples t-test was used for comparing means between groups. The chi-squared test or Fisher's exact test as appropriate were applied to compare the proportions between groups. A p-value = 0.05 was taken to be significant.
Logistic regression models were applied to identify significant risk factors which were predictive of osteonecrosis including age, gender, weight, body mass index, duration of therapy, peak, mean daily and cumulative methylpredni so lone-equivalent doses, past disease history (including use of topical corticosteroids), past and present smoking habits and alcohol consumption.
Only 114 of the original 121 patients had detailed survey results and underwent evaluation by MRI (Table I). There were 80 women and 34 men of whom 25 (21.9%) were doctors, 79 (69.3%) nurses and ten (8.8%) were in other occupations.
Bar chart showing the distribution of the 145 osteonecrotic lesions in 43 patients with osteonecrosis.
Bar chart showing the distribution of 145 osteonecrotic lesions by multifocal and non-multifocal osteonecrosis grouping.
Table II. Methylprednisolone-equivalent doses and duration of therapy in patients with either multifocal or non-multifocal ostaonecrosis
Table III. Methylprednisolone-equivalent doses and duration of therapy in patients wuth both epiphyseal and diaphyseal lesions and with isolated epiphyseal lesions
Of the 114 patients, 43 (37,7%) were found to have osteonecrosis. A total of 145 ARCO stage-I osteonecrotic lesions were detected by T^sub 1^-weighted coronal imaging. The distribution of the lesions is shown in Figure 1. Of the 43 affected patients, 30 (69.8%) had only one or two areas of osteonecrosis and in these, involvement of the joints was the most common presentation, 53 of the 57 sites being epiphyseal and four diaphyseal (Fig. 2). The other 13 patients (30.2%) had multifocaf osteonecrosis affecting between three and seven sites. In this group there were 65 epiphyseal lesions, principally involving the hip, knees and shoulders, and 23 diaphyseal lesions (Fig. 2). Diaphyseal lesions occurred in patients with multifocal osteonecrosis more commonly than in those with uni- or bifocal osteonecrosis (Fisher's exact two-sided test, p = 0.004).
Intravenous methylprednisolone (40 mg/day to 980 mg/ day) and oral prednisone (2.5 mg/day to 20 mg/day) had been administered to all patients within a mean period of 28.2 days (6 to 72). It was initially given to those who were deteriorating and was stopped when they began to recover. The mean time interval between starting steroid therapy and follow-up was 6.5 months (5 to 8).
Logistic regression analysis showed that the peak methylprednisolone-equivalent dose was the principal risk factor for uni- or bifocal osteonecrosis (p
Bar chart showing the distribution of osteonecrosis and multifocal osteonecrosis in 114 patients by cumulative methyl p rednisolone-equivalent dose grouping.
Bar chart showing the distribution of osteonecrosis cases and multifocal ostenecrosis cases in 114 patients by peak methyl prednisolone-equivalent dose grouping. Fig. 5
Bar chart showing the distribution of osteonecrosis and multifocal osteonecrosis in 114 patients by duration of treatment.
Table IV. The risk of osteonecrosis and multifocal osteonecrosis according to methylprednisolone-equivalent doses and duration of therapy
The 43 patients with osteonecrosis had received significantly higher cumulative and peak methylprednisolone-equivalent doses and had been treated for longer than the 71 without osteonecrosis (Table I). The 13 patients with multifocal osteonecrosis received a significantly higher cumulative methylprednisolone-equivalent dose than the 30 with uni- or bifocal osteonecrosis (Table II). The patients with both epiphyseal and diaphyseal lesions received a significantly higher cumulative methylprednisolone-equivalent dose than those with only epiphyseal lesions (Table III). The distribution and risk of osteonecrosis and multifocal osteonecrosis are shown in Figures 3 to 5 and in Table IV.
Patients with osteonecrosis were no more likely to smoke, have a high alcohol intake, have a combined condition (smoking and alcohol abuse), or take other medication than those without osteonecrosis (Table I). Logistic regression analysis revealed that these variables were not significant risk factors for osteonecrosis (gender, p = 0.358; age, p = 0.461; weight, p = 0.33; height, p = 0.767; BMI, p = 0255; smoking, p = 0.772; alcohol, p = 0.204).
SARS is a newly described infectious disease, caused by the SARS- CoV.5,6 It mainly targets the immune system and seems to infect a variety of cell types in different organs. Despite this, in situ hybridisation and immunohistochemical tests have detected neither viral genomic sequences nor antigens in bone marrow. Both viral isolation and reverse transcriptase polymerase chain reaction tests performed on bone marrow have been negative.5 Other studies of patients infected with SARS have reported no signs of osteonecrosis when steroids have not been used8,11 and therefore the latter is clearly associated with osteonecrosis.1 The incidence of osteonecrosis in SARS patients is generally believed to be related to steroid therapy.1 We have assumed, therefore on the basis of this limited evidence, that the SARS-CoV does not itself cause osteonecrosis and that steroid administration is an independent variable for SARS-related osteonecrosis.
Our study was performed after a mean of 6.5 months (5 to 8) from the initial treatment with steroids. It confirmed that the number of osteonecrotic lesions was directly related to the dosage of steroids and that a very high dose, more than 200 mg peak dose and more than 4000 mg cumulative methylprednisolone-equivalent doses, was a significant risk factor for multifocal epiphyseal and diaphyseal osteonecrosis. The distribution of the osteonecrotic lesions in multifocal osteonecrosis has been documented previously by several authors.2,3 In our study, we found a similar pattern, with a high incidence in the femoral head, knee and head of the humerus. None of the previous reports mentioned osteonecrosis of the shafts of long bones in patients with multifocal osteonecrosis.2,3 In the 13 patients with multifocal osteonecrosis in our series, the shafts of the long bones were frequently affected which suggests that if a patient is found to have an osteonecrotic lesion in such a location, multifocal osteonecrosis should be suspected.
It has been suggested, that total-body isotope bone scanning should be used to screen for multifocal lesions.12,13 However, several authors have remarked on its lack of sensitivity in the early stages of the disease. It is not thought to be the best method of diagnosis and neither is it a good method for screening the opposite hip in patients with osteonecrosis of the femoral head.12,13
We found a higher incidence of osteonecrosis and multifocal osteonecrosis using Tt-weighted coronal views than has previously been reported. The causal relationship between steroids and multifocal osteonecrosis may be due to differing vascular reactivity of each part of the skeleton as well as to the action of steroids on the circulation. Recent studies in animals have shown that the influence of steroids on vasoreactivity appears to be species- and tissue-dependent.14-20 On this basis the femoral head would be most reactive to vasoconstriction with a higher sensitivity to relatively low doses of steroids, and the shafts of long bones the least reactive.
No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
1. Jones LC, Hungerford DS. The pathogenesis of osteonecrosis. Instr Course Lect 2007;56:179-96.
2. No authors listed. Symptomatic multifocal osteonecrosis: a multicenter study: Collaborative Osteonecrosis Group. Clin Orthop 1999;369:312-26.
3. LaPorte OM, Mont MA, Mohan V, Jones LC, Hungerfod DS. Multifocal osteonecrosis. J Rheumatol 1998;25:1968-74.
4. Mankin HJ. Pathophysiology of osteonecrasis. Seminars in arthroplasty 2007;18:170-4.
5. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007;170:1136-47.
6. Chan MH, Chan PK, Griffith JF, at al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology 2006;38:229-35.
7. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005;235:168-75.
8. Li Z-P, Sun W, Qu H, at al. Clinical research of correlation between osteonecrosis and steroid. Zhonghua Waike Za Zhi 2005;43:1048-53 (in Chinese).
9. No authors listed. World Health Organisation. Case definitions for surveillance of severe acute respiratory Syndrome (SARS) http:// www.who.int/csr/sars/casedefinition/en/(date last accessed 24 December 2007).
10. Gardeniers JWM. ARCO Committee on Terminology and Staging. ARCO Newsletter 1993;5:79-82. http://www.arco-intl.org/Newsletters/ Gardeniers-1993-5-2/Gardeniers-1993.htm (date last accessed 28 July 2008).
11. Shen J, Liang BL, Zeng QS, et al. Investigation of proximal femoral marrow with magnetic resonance imaging in recovered patients with severe acute respiratory syndrome. Zhonghua Jie He He Hu Xi Za Zhi 2006;29:189-931 in German).
12. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg [Am] 1995;77-A:459-74.
13. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg [Am] 2006;88- A:1117-32.
14. Drescher W, Schneider T, Becker C, et al. Selective reduction of bone blood flow by short-term treatment with high-dose methylprednisolone: an experimental study in pigs. J Bone Joint Surg [Br] 2001;83-B:274-7.
15. Schomig A, Luth B, Diatz R, Gross F. Changes in vascular smooth muscle sensitivity to vasoconstrictor agents induced by corticosteroids, adrenalectomy and differing salt intake in rats. Clin Sci Mol Med Suppl 1976;3:61-3.
16. Hirano K, Tsutsui H, Sugioka Y, Sueishi K. Histopathologic alterations of retinacular vessels and osteonecrosis. Clin Orthop 1997;342:192-204.
17. Driessens M, Vanhoutte PM. Vascular reactivity of the isolated tibia of the dog. Am J Physiol 1979;236:904-8.
18. Lundgaard A, Aalkjaer C, Holm-Nielsen P, Mulvany MJ, Hansen ES. Method for assessment of vascular reactivity in bone: in vitro studies on resistance arteries isolated from porcine cancellous bone. J Orthop Res 1996;14:962-71.
19. Drescher W, Weigert KP, Bunger MH, et al. Femoral head blood flow reduction and hypercoagulabiltty under 24 h megadose steroid treatment in pigs. J Orthop Res 2004;22:501-8.
20. Drescher W, Li H, Lundgaard A, Bunger CE, Hansen ES. Endothelin-1-induced femoral head epiphyseal artery constriction enhanced by long-term corticosteroid treatment J Bone Joint Surg [Am] 2006;88-A(Suppl 3):173-9.
Z. R. Li,
From the China-Japan
* N.-F. Zhang, M D, Orthopaedic
Surgeon, Associate Professor
* Z. R. Li, MD, Orthopaedic
Surgeon, Chief and Professor
* H.-Y Wei, MD, PhD,
* Z.-H. Liu, MD, PhD,
Department of Orthopaedic
Center of Osteonecrosis and
Joint Preserving &
Friendship Hospital, 2 Yinghua
East Road, Chaoyang District,
Beijing, People's Republic of
* P. Hernigou. MD, Professor
Hopital Henri Mondor,
University Paris XII, 51 avenue
du Marechal de Lattre de
Tassigny, 94010 Creteil, France.
Correspondence should be sent to Professor N.-F. Zhang; e-mail: [email protected]
(c)2008 British Editorial Society of Bone and Joint Surgery
doi:10.1302/0301-620X.90B9. 20056 $2.00
J Bone Joint Surg [Br] 2008;90-B: 1239-43.
Received 6 August 2007; Accepted after revision 16 April 2008
Copyright British Editorial Society of Bone & Joint Surgery Sep 2008
(c) 2008 Journal of Bone and Joint Surgery; British volume. Provided by ProQuest LLC. All rights Reserved.